[go: up one dir, main page]

NO20092357L - Polymorfe former av en mGluR5 reseptorantagonist - Google Patents

Polymorfe former av en mGluR5 reseptorantagonist

Info

Publication number
NO20092357L
NO20092357L NO20092357A NO20092357A NO20092357L NO 20092357 L NO20092357 L NO 20092357L NO 20092357 A NO20092357 A NO 20092357A NO 20092357 A NO20092357 A NO 20092357A NO 20092357 L NO20092357 L NO 20092357L
Authority
NO
Norway
Prior art keywords
mglur5 receptor
receptor antagonist
polymorphic forms
treatment
receptor
Prior art date
Application number
NO20092357A
Other languages
English (en)
Other versions
NO342451B1 (no
Inventor
Shan-Ming Kuang
Thomas P Cleary
Alexander Glomme
Olaf Grassmann
Roland Meier
Doreen Miller
Regina Moog
Franziska E Rohrer
Jason Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092357(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20092357L publication Critical patent/NO20092357L/no
Publication of NO342451B1 publication Critical patent/NO342451B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår mono-sulfat- og hemi-sulfatsalter av 2-klor-4-[1-(4-fluorfenyl)-2,5-dimetyl-1H-imidazol-4-yletynyl]pyridin, krystallinske og amorfe former derav, og anvendelse av dem i farmasøytiske formuleringer. De foreliggende forbindelser er aktive på mGluR5-reseptoren for behandling av sykdommer relatert til denne reseptoren, så som akutte og/eller kroniske nevrologiske lidelser, spesielt angst, eller for behandling av kronisk og akutt smerte, beskyttelse mot leverskade, svikt, enten den er medikament- eller sykdomsbevirket, urininkontinens, fedme, fragilt X-syndrom eller autisme. 270 25
NO20092357A 2006-12-21 2009-06-19 Krystallinsk form av mono-sulfatsaltet av 2-klor-4-[1-(4-fluorfenyl)-2,5-dimetyl-1H-imidazol-4-yletynyl]pyridin fremgangsmåte for fremstilling, farmasøytisk preparat samt anvendelse for behandling av sykdom NO342451B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87639806P 2006-12-21 2006-12-21
PCT/EP2007/063721 WO2008074697A1 (en) 2006-12-21 2007-12-11 Polymorphs of a mglur5 receptor antagonist

Publications (2)

Publication Number Publication Date
NO20092357L true NO20092357L (no) 2009-07-15
NO342451B1 NO342451B1 (no) 2018-05-22

Family

ID=39186951

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092357A NO342451B1 (no) 2006-12-21 2009-06-19 Krystallinsk form av mono-sulfatsaltet av 2-klor-4-[1-(4-fluorfenyl)-2,5-dimetyl-1H-imidazol-4-yletynyl]pyridin fremgangsmåte for fremstilling, farmasøytisk preparat samt anvendelse for behandling av sykdom

Country Status (32)

Country Link
US (2) US8063076B2 (no)
EP (1) EP2125779B1 (no)
JP (1) JP5405311B2 (no)
KR (1) KR101148580B1 (no)
CN (1) CN101568531B (no)
AR (1) AR064654A1 (no)
AU (1) AU2007336369B2 (no)
CA (1) CA2673444C (no)
CL (1) CL2007003695A1 (no)
CO (1) CO6210731A2 (no)
CY (1) CY1117810T1 (no)
DK (1) DK2125779T3 (no)
EC (1) ECSP099431A (no)
ES (1) ES2577391T3 (no)
HR (1) HRP20160950T1 (no)
HU (1) HUE029324T2 (no)
IL (1) IL199181A (no)
MA (1) MA31008B1 (no)
MX (1) MX2009006694A (no)
MY (1) MY148217A (no)
NO (1) NO342451B1 (no)
NZ (1) NZ577440A (no)
PE (1) PE20081484A1 (no)
PL (1) PL2125779T3 (no)
PT (1) PT2125779T (no)
RS (1) RS54853B1 (no)
RU (1) RU2460728C2 (no)
SI (1) SI2125779T1 (no)
TW (1) TWI347320B (no)
UA (1) UA96970C2 (no)
WO (1) WO2008074697A1 (no)
ZA (1) ZA200904289B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2125779T (pt) 2006-12-21 2016-07-19 Hoffmann La Roche Polimorfos de um antagonista de um recetor de mglur5
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
MX2013010698A (es) 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
GB201317022D0 (en) * 2013-09-25 2013-11-06 Addex Pharmaceuticals Sa Polymorphs
CA2936377A1 (en) 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating egfr expressing tumors
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
KR20230027145A (ko) 2020-06-05 2023-02-27 노에마 파르마 아게 결절성 경화증 복합증의 치료 방법
TW202220649A (zh) * 2020-07-30 2022-06-01 瑞士商諾埃瑪製藥公司 三叉神經痛之治療方法
CN120459099A (zh) * 2025-06-17 2025-08-12 北京大学成都前沿交叉生物技术研究院 mGlu5抑制剂在治疗或预防非酒精性脂肪肝病和/或肥胖、改善瘦素敏感性方面的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303199A (en) 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (de) 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (en) 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
US4508560A (en) 1981-11-11 1985-04-02 Ciba Geigy Corporation Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use
US4711962A (en) 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
AU644802B2 (en) 1989-06-30 1993-12-23 E.I. Du Pont De Nemours And Company Substituted imidazoles
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
CN1154489C (zh) 1997-08-14 2004-06-23 弗·哈夫曼-拉罗切有限公司 抗神经学疾病的杂环乙烯基醚
AU780009B2 (en) 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
JP5154728B2 (ja) 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
MXPA03004862A (es) 2000-12-04 2005-02-14 Hoffmann La Roche Derivados de feniletenilo o feniletinilo como antagonistas del receptor de glutamato.
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
AU2002360621B2 (en) 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en) 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives
US7452909B2 (en) 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
ATE397601T1 (de) * 2004-06-01 2008-06-15 Hoffmann La Roche Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
PT2125779T (pt) 2006-12-21 2016-07-19 Hoffmann La Roche Polimorfos de um antagonista de um recetor de mglur5

Also Published As

Publication number Publication date
CY1117810T1 (el) 2017-05-17
CL2007003695A1 (es) 2008-07-04
HRP20160950T1 (hr) 2016-10-07
HUE029324T2 (en) 2017-02-28
TW200833679A (en) 2008-08-16
KR101148580B1 (ko) 2012-05-24
AU2007336369A1 (en) 2008-06-26
EP2125779B1 (en) 2016-04-27
KR20090081026A (ko) 2009-07-27
SI2125779T1 (sl) 2016-07-29
MY148217A (en) 2013-03-29
CN101568531B (zh) 2013-11-13
RS54853B1 (sr) 2016-10-31
TWI347320B (en) 2011-08-21
DK2125779T3 (en) 2016-07-04
CA2673444C (en) 2015-01-20
US20080312288A1 (en) 2008-12-18
ECSP099431A (es) 2009-07-31
RU2460728C2 (ru) 2012-09-10
PE20081484A1 (es) 2008-10-18
BRPI0720954A2 (pt) 2014-03-18
US8063076B2 (en) 2011-11-22
NZ577440A (en) 2011-12-22
EP2125779A1 (en) 2009-12-02
CN101568531A (zh) 2009-10-28
WO2008074697A1 (en) 2008-06-26
RU2009123135A (ru) 2011-01-27
ES2577391T3 (es) 2016-07-14
NO342451B1 (no) 2018-05-22
US20120035222A1 (en) 2012-02-09
MA31008B1 (fr) 2009-12-01
PL2125779T3 (pl) 2016-11-30
US8329912B2 (en) 2012-12-11
AU2007336369B2 (en) 2013-01-17
ZA200904289B (en) 2010-04-28
JP5405311B2 (ja) 2014-02-05
PT2125779T (pt) 2016-07-19
MX2009006694A (es) 2009-06-30
JP2010513378A (ja) 2010-04-30
AR064654A1 (es) 2009-04-15
IL199181A (en) 2016-02-29
CA2673444A1 (en) 2008-06-26
UA96970C2 (en) 2011-12-26
CO6210731A2 (es) 2010-10-20

Similar Documents

Publication Publication Date Title
NO20092357L (no) Polymorfe former av en mGluR5 reseptorantagonist
EP2178870A4 (en) INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
WO2006110816A3 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
WO2009036996A3 (en) Small molecule bradykinin b1 receptor antagonists
BRPI0812504B8 (pt) composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
NO20073932L (no) Fuserte bicykliske karboksamidderivater for anvendelse som CXCR2 inhibitorer i behandlingen av inflammasjon
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
WO2009035997A3 (en) Benzo-fused heterocycles
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
BRPI0514736A (pt) inibidores do receptor sigma
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
WO2010021882A3 (en) Cold menthol receptor antagonists
CL2007002427A1 (es) Compuestos derivados heterociclicos, inhibidores de metaloproteinasa de matriz; proceso de preparacion; composicion farmaceutica, util para el tratamiento o profilaxis de enfermedades inflamatorias o desordenes autoinmunes.
WO2008012338A3 (en) Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions